ArticlePharmacological reports : PR2026
The anti-CEACAM1 agonistic antibody CCM5.01 inhibits the growth of colon cancer cell lines in 2D and 3D models.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is an inhibitory receptor expressed by multiple tumors, including colorectal cancer (CRC). CEACAM1 exists as a long isoform (L) containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a short isoform (S) lacking ITIMs. While microsatellite instability (MSI) CRCs respond to immunotherapy, microsatellite-stable (MSS) CRCs remain resistant, highlighting the need for alternative therapeutic targets. We previously developed an agonistic anti-CEACAM1 monoclonal antibody (mAb), CCM5.01, and demonstrated its CEACAM1-dependent inhibitory effects in melanoma. Here, we evaluated CCM5.01 inhibitory activity on CRC cell lines and related it to L/S ratio.
methodsCRC cell lines HT-29, LOVO, and HCT-116 were treated with CCM5.01 and analyzed by proliferation assays before and after transfection with L or S CEACAM1 isoforms. Transfected cells treated with CCM5.01 were analyzed for signaling and in 3D spheroid models.
resultsCEACAM1-positive CRC cells showed dose-dependent inhibition in response to CCM5.01 treatment and were associated with L/S isoform expression. High CEACAM1-L expression induced growth inhibition and apoptosis, while CEACAM1-S promoted cellular activity. Similar isoform-dependent effects were observed in spheroid models.
conclusionsCEACAM1-mediated signaling in CRCs critically depends on the L/S isoform ratio, supporting CEACAM1-targeted activating therapy as a potential strategy in both MSI and immunotherapy-resistant MSS CRC.
Indexed as
Identifiers
42671771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.